Ligand PharmaceuticalsFRA:LGDN +0.79%76 Quick Ratio is 21.00 as of Mar. 2026, which is 173% above its 10-year median of 7.70. GuruFocus rates FRA:LGDN with a GF Score™ of 76/100 and a GF Value™ of €147.69 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,412 Biotechnology companies, Ligand Pharmaceuticals ranks better than 93.27% on this metric.
Ligand Pharmaceuticals has a quick ratio of 21.00. It generally indicates good short-term financial strength.
The historical rank and industry rank for Ligand Pharmaceuticals's Quick Ratio or its related term are showing as below:
FRA:LGDN'
s Quick Ratio Range Over the Past 10 Years
Min: 0.56 Med: 7.7 Max: 65.66
Current: 21
During the past 13 years, Ligand Pharmaceuticals's highest Quick Ratio was 65.66. The lowest was 0.56. And the median was 7.70.
FRA:LGDN's Quick Ratio is ranked better than 93.27% of 1412
companies
in the Biotechnology industry
Industry Median: 3.6
vs FRA:LGDN: 21.00
Ligand Pharmaceuticals (FRA:LGDN) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Ligand Pharmaceuticals Quick Ratio Related Terms
Ligand Pharmaceuticals Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:LGDN vs DFTX, CGON, XENE: Quick Ratio Comparison
For the Biotechnology subindustry, Ligand Pharmaceuticals's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ligand Pharmaceuticals Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ligand Pharmaceuticals's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Ligand Pharmaceuticals's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Ligand Pharmaceuticals's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ligand Pharmaceuticals (FRA:LGDN) has a Quick Ratio of 21.00 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Ligand Pharmaceuticals and its competitors. This is 173% above median its historical median of 7.70. Over the past decade, Ligand Pharmaceuticals' Quick Ratio has ranged from 0.56 to 65.66. According to the industry distribution chart, Ligand Pharmaceuticals ranks #95 out of 1412 companies in the Biotechnology industry, placing it in the top 6.7%.
Is Ligand Pharmaceuticals' Quick Ratio too high?
Ligand Pharmaceuticals' current Quick Ratio of 21.00 is 173% above median its 10-year median of 7.70. Over the past 10 years, this metric has ranged from a low of 0.56 to a high of 65.66. The Biotechnology industry median Quick Ratio is 3.60. Ligand Pharmaceuticals' value of 21.00 is 483.3% above this industry median. Based on the distribution chart, Ligand Pharmaceuticals ranks #95 out of 1412 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Ligand Pharmaceuticals has a GF Score™ of 76/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ligand Pharmaceuticals' Quick Ratio compare to DFTX and CGON?
According to the Biotechnology industry distribution chart, Ligand Pharmaceuticals ranks #95 out of 1412 companies for Quick Ratio. This places Ligand Pharmaceuticals in the top 7% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.60. Ligand Pharmaceuticals' value of 21.00 is 483.3% above this benchmark. Historically, Ligand Pharmaceuticals' own Quick Ratio has ranged from 0.56 to 65.66 over the past decade. While the company's 10-year median is 7.70 vs. the industry median of 3.60, Ligand Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ligand Pharmaceuticals's current Quick Ratio of 21.00 is 483.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Ligand Pharmaceuticals and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ligand Pharmaceuticals's current Quick Ratio is 21.00, which is 173% above median its own 10-year median of 7.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ligand Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Ligand Pharmaceuticals (FRA:LGDN) is currently considered Significantly Overvalued. The stock's GF Value™ is €147.69, compared to a current price of €254.00 — trading 72% above its estimated fair value. The current Quick Ratio is 21.00, which is 173% above median its 10-year median of 7.70 and 483.3% above the Biotechnology industry median of 3.60. Ligand Pharmaceuticals' overall GF Score™ is 76/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Ligand Pharmaceuticals (FRA:LGDN), the current Quick Ratio is 21.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ligand Pharmaceuticals (FRA:LGDN) Overvalued in 2026?
Based on GuruFocus' analysis, Ligand Pharmaceuticals stock appears to be overvalued.
The current stock price of €254.00 is trading 72% above its estimated GF Value™ of €147.69.
GuruFocus considers Ligand Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for FRA:LGDN:
Quick Ratio: 21.00 (173% above median its 10-year median of 7.70)
GF Value™: €147.69 vs. price of €254.00 (72% above fair value)
Industry Position: 483.3% above the Biotechnology median (#95 of 1412)
No single metric tells the full story. See the FRA:LGDN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
76GF Score
Get the complete analysis for FRA:LGDN
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LGDN has been successfully added to your 
